Compare COGT & WAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | COGT | WAY |
|---|---|---|
| Founded | 2014 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.5B | 6.7B |
| IPO Year | 2018 | 2024 |
| Metric | COGT | WAY |
|---|---|---|
| Price | $39.70 | $29.48 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 14 | 15 |
| Target Price | $32.08 | ★ $46.53 |
| AVG Volume (30 Days) | ★ 2.2M | 1.7M |
| Earning Date | 02-24-2026 | 02-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.62 |
| Revenue | N/A | ★ $1,039,842,000.00 |
| Revenue This Year | N/A | $16.69 |
| Revenue Next Year | N/A | $17.71 |
| P/E Ratio | ★ N/A | $47.53 |
| Revenue Growth | N/A | ★ 14.76 |
| 52 Week Low | $3.72 | $28.71 |
| 52 Week High | $43.73 | $48.11 |
| Indicator | COGT | WAY |
|---|---|---|
| Relative Strength Index (RSI) | 61.99 | 36.34 |
| Support Level | $37.70 | $28.71 |
| Resistance Level | $40.40 | $34.65 |
| Average True Range (ATR) | 1.90 | 1.25 |
| MACD | 0.31 | -0.21 |
| Stochastic Oscillator | 83.19 | 17.00 |
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.
Waystar Holding Corp is a provider of mission-critical cloud technology to healthcare organizations. its enterprise-grade platform transforms the complex and disparate processes comprising healthcare payments received by healthcare providers from payers and patients, from pre-service engagement through post-service remittance and reconciliation. its platform enhances data integrity, eliminates manual tasks, and improves claim and billing accuracy, which results in transparency, reduced labor costs, and faster, more accurate reimbursement and cash flow. The market for solutions extends throughout the United States and includes Puerto Rico and other USA Territories.